Section 4725.31 | Clinically significant drug-induced side effects.
You are viewing a past version of this section that is no longer in effect
View Current Version
Effective:
March 9, 1999
Legislation:
House Bill 553 - 122nd General Assembly
An optometrist licensed by the state board of optometry shall promptly report to the board any instance of a clinically significant drug-induced side effect in a patient due to the optometrist's administering, employing, applying, or prescribing a topical ocular or therapeutic pharmaceutical agent to or for the patient. The board, by rule adopted in accordance with Chapter 119. of the Revised Code, shall establish reporting procedures and specify the types of side effects to be reported. The information provided to the board shall not include the name of or any identifying information about the patient.
Available Versions of this Section
- March 9, 1999 – House Bill 553 - 122nd General Assembly [ View March 9, 1999 Version ]
- January 21, 2018 – Amended by House Bill 49 - 132nd General Assembly [ View January 21, 2018 Version ]